A patient with acute lymphocytic leukemia in relapse, who developed severe herpetic gingivostomatitis, was treated with cytosine arabinoside (Ara-C). The titer of herpes simplex virus isolated from the mouth showed a rapid but transient decline following iv administration of Ara-C on two separate occasions. In-vitro studies revealed that the inactivating effect of saliva on herpesvirus was cancelled by antibody to IgA. These observations suggest that the diminution of the amount of herpesvirus isolated from the mouth after treatment was probably the result of inhibition of new viral synthesis by Ara-C coincident with neutralization of preformed virus by secretory IgA. Cytosine arabinoside (Ara-C) inhibited the multiplication of several DNA viruses in mammalian cell cultures [1, 2]. These observations have led to the experimental use of this drug in the treatment of life-threatening viral infections [3-6]. Reports of the efficacy of Ara-C in the treatment of these illnesses, however, have been based mainly on clinical impressions. A patient with acute lymphocytic leukemia in relapse who developed severe herpetic gingivostomatitis provided an opportunity to obtain quantitative data on the effect of Ara-C on synthesis of herpes simplex virus (HSV) in vivo. The inhibition of new viral synthesis by Ara-C provided an opportunity to study the role of secretory IgA in the elimination of HSV.
[1]
M. Hirsch,et al.
Selective effects of anti-macrophage serum, silica and anti-lymphocyte serum on pathogenesis of herpes virus infection of young adult mice.
,
1970,
Journal of immunology.
[2]
B. Juel-Jensen.
Severe generalized primary herpes treated with cytarabine.
,
1970,
British medical journal.
[3]
B. Juel-Jensen.
Varicella and cytosine arabinoside.
,
1970,
Lancet.
[4]
S. Plotkin,et al.
Treatment of congenital cytomegalic inclusion disease with antiviral agents.
,
1969,
Antimicrobial agents and chemotherapy.
[5]
P. Rompf,et al.
Treatment of varicella-zoster with cytosine arabinoside.
,
1969,
Transactions of the Association of American Physicians.
[6]
P. Carbone,et al.
A clinical evaluation of dose and schedule of administration of cytosine arabinoside (NSC 63878).
,
1968,
Cancer research.
[7]
R. Talley,et al.
Clinical pharmacology and human antitumor activity of cytosine arabinoside
,
1967,
Cancer.
[8]
F. Rapp.
INHIBITION BY METABOLIC ANALOGUES OF PLAQUE FORMATION BY HERPES ZOSTER AND HERPES SIMPLEX VIRUSES.
,
1964,
Journal of immunology.
[9]
P. Brunell,et al.
CRUDE TISSUE CULTURE ANTIGEN FOR DETERMINATION OF VARICELLA-ZOSTER COMPLEMENT FIXING ANTIBODY.
,
1964,
Public health reports.